News

Published on 27 Feb 2023 on Insider Monkey via Yahoo Finance

Foreign Currency Headwinds Dragged Glaukos Corporation (GKOS) Shares in Q4


Article preview image

Alger Capital, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. During the quarter, Class A shares of the fund underperformed the Russell 2500 Growth Index. The fund returned 3.01% (without sales charges) compared to 4.72% for the benchmark. The Energy and Industrials sectors contributed to the fund’s relative performance in the quarter, while Information Technology and Health Care sectors detracted from performance. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Alger Weatherbie Specialized Growth Fund highlighted stocks like Glaukos Corporation (NYSE:GKOS) in the Q4 2022 investor letter. Headquartered in San Clemente, California, Glaukos Corporation (NYSE:GKOS) is an ophthalmic medical technology and pharmaceutical company. On February 24, 2023, Glaukos Corporation (NYSE:GKOS) stock closed at $47.60 per share. One-month return of Glaukos Corporation (NYSE:GKOS) was -1.41%, and its shares lost 13.94% of their value over the last 52 weeks. Glaukos Corporation (NYSE:GKOS) has a market capitalization of $2.273 billion.

Alger Weatherbie Specialized Growth Fund made the following comment about Glaukos Corporation (NYSE:GKOS) in its Q4 2022 investor letter:

NYSE.GKOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Glaukos Corporation GKOS reported fourth-quarter 2024 adjusted loss of 40 cents per share, narrow...

Zacks · via Yahoo Finance 21 Feb 2025

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 90% Above Its...

Key Insights The projected fair value for Glaukos is US$299 based on 2 Stage Free Cash Flow to...

Simply Wall St. · via Yahoo Finance 3 Feb 2025

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial result...

Zacks · via Yahoo Finance 9 Jan 2025

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

Shares of Glaukos Corporation GKOS scaled a new 52-week high of $155.76 on Jan. 6, before closing...

Zacks · via Yahoo Finance 7 Jan 2025

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

Glaukos Corporation GKOS recently announced that it has submitted its New Drug Application (NDA) ...

Zacks · via Yahoo Finance 24 Dec 2024

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial result...

Zacks · via Yahoo Finance 11 Dec 2024

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

GKOS stock gains from strong product demand, international expansion and pipeline progress, which...

Zacks · via Yahoo Finance 21 Nov 2024

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst - Glaukos...

Thursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...

Benzinga 3 May 2024

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Glaukos Corporation GKOS reported first-quarter 2024 adjusted loss of 70 cents per share, which i...

Zacks via Yahoo Finance 3 May 2024

Glaukos stock price target raised on strong Q1 sales By Investing.com

On Thursday, Glaukos Corporation (NYSE:GKOS) received an updated stock price target from Needham,...

Investing.com 3 May 2024